Literature DB >> 10379696

Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.

C M Tangen1, G G Koch.   

Abstract

Many clinical trials have time-to-event variables as principal response criteria. When adjustment for covariates is of some importance, the relative role of methods for such analysis may be of some concern. For the Wilcoxon and logrank tests, there is an issue of how covariance adjustment can be nonparametric in the sense of not involving any further assumptions beyond those of the logrank and Wilcoxon test. Also of particular interest in a clinical trial is the estimation of the difference between survival probabilities for the treatment groups at several points in time. As with the Wilcoxon and logrank tests, there is no well known nonparametric way to incorporate covariate adjustment into such estimation of treatment effects for survival rates. We propose a method that enables covariate adjustment for hypothesis testing with logrank or Wilcoxon scores. Related extensions for applying covariate adjustment to estimation of treatment effects are provided for differences in survival-rate counterparts to Kaplan-Meier survival rates. The results represent differences in population average survival rates with adjustment for random imbalance of covariates between treatment groups. The methods are illustrated with a clinical trial example.

Mesh:

Substances:

Year:  1999        PMID: 10379696     DOI: 10.1081/BIP-100101179

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  6 in total

1.  Efficiency improvement in a class of survival models through model-free covariate incorporation.

Authors:  Tanya P Garcia; Yanyuan Ma; Guosheng Yin
Journal:  Lifetime Data Anal       Date:  2011-04-01       Impact factor: 1.588

2.  Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials.

Authors:  Min Zhang
Journal:  Lifetime Data Anal       Date:  2014-02-13       Impact factor: 1.588

3.  Increasing power in randomized trials with right censored outcomes through covariate adjustment.

Authors:  K L Moore; M J van der Laan
Journal:  J Biopharm Stat       Date:  2009-11       Impact factor: 1.051

4.  A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data.

Authors:  Benjamin R Saville; Amy H Herring; Gary G Koch
Journal:  Stat Med       Date:  2010-01-15       Impact factor: 2.373

5.  Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

6.  Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.

Authors:  V Georgoulias; A Agelidou; K Syrigos; A Rapti; M Agelidou; J Nikolakopoulos; A Polyzos; A Athanasiadis; E Tselepatiotis; N Androulakis; K Kalbakis; G Samonis; D Mavroudis
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.